Navigation Links
Fighting sleeping sickness with X-ray lasers
Date:12/21/2012

This press release is available in German.

Using the world's most powerful X-ray free-electron laser, an international team of researchers, including scientists of the Max Planck Institute for Medical Research in Heidelberg, has obtained new insight into the structure of a medicinally important protein that may serve as a blueprint for the development of drugs to fight sleeping sickness. Science magazine have chosen the experimental study as one of the top ten scientific breakthroughs of the year.

Sleeping sickness is caused by the unicellular organism Trypanosoma brucei that is transmitted by tsetse flies. The disease kills about 30,000 people word-wide each year. The currently available drugs against the disease are of limited efficacy and can have severe side effects. Moreover, resistance against them is increasing. A promising drug target is the protein Cathepsin B whose enzymatic activity is vital for the parasite's survival. Inhibitors of Cathepsin B need to be highly specific against the trypanosomal variant because it resembles the human form. The featured work provides detailed insight into the structure of trypanosomal Cathepsin B in a natively inhibited form that might serve as a blueprint for the rational design of drugs. The biologically important form of the protein was obtained by a trick: instead of crystallizing the protein in plastic trays in the lab, it was crystallized in vivo in the cells that produced the protein. This approach provides natively modified proteins, but the crystals obtained are tiny.

The use of the X-ray free-electron laser (FEL) at Stanford was essential for the work. Protein structures are typically determined by exposing crystals of the protein to X-rays. Unfortunately, many of the most interesting proteins, such a membrane proteins, do not form crystals of sufficient size for analysis by conventional X-ray sources. Measurements using very tiny crystals have now become feasible thanks to the extreme intensity of FELs whose ultrashort pulse durations outrun most radiation damage effects. It is these properties that allowed structure analysis of the tiny in-vivo grown Cathepsin B crystals. Using a model system, the Heidelberg researchers and their international colleagues had previously validated this new approach using FELs as a tool for structure analysis, an important step in the method development that published in February 2012 in Science. The current featured research demonstrates for the first time FEL use to obtain new biologically important information. The international team shows in detail how the structures of typanosomal and human Cathepsin B differ and how the naturally occurring native inhibitor binds . This may provide new ideas for designing drugs against sleeping sickness.

The team included researchers from the Max Planck Institute for Medical Research, Heidelberg, the Center of Free-Electron Laser Science at Deutschen Elektronen-Synchrotron DESY, the Arizona State University, the Universities of Hamburg, Lbeck, Tbingen, Uppsala and Gteborg, the SLAC National Accelerator Center (USA), the Lawrence Livermore National Laboratory (USA) and the Max Planck Advanced Study Group at the Hamburg Center for Free-Electron Laser Science (CFEL).


'/>"/>
Contact: Dr. Ilme Schlichting
ilme.schlichting@mpimf-heidelberg.mpg.de
49-622-148-6500
Max-Planck-Gesellschaft
Source:Eurekalert  

Related medicine news :

1. From a Failed Vaccine, New Insights Into Fighting HIV
2. Doctors Detail High Costs of Fighting Malpractice Claims
3. Soybeans soaked in warm water naturally release key cancer-fighting substance
4. Living longer - variability in infection-fighting genes can be a boon for male survival
5. 2-1-1 could be effective tool in fighting cancer disparities
6. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
7. Parents Fighting May Have Long-Lasting Effect on Kids
8. Why current strategies for fighting obesity are not working
9. Ordinary chickens may be extraordinary in fighting cancer, says Texas A&M researcher
10. Fighting obesity with thermal imaging
11. Male Ontario students show declines in fighting; females show elevated bullying and mental distress
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fighting sleeping sickness with X-ray lasers
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: